Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells $591,758.52 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Denali Therapeutics Price Performance

DNLI stock opened at $19.10 on Friday. The stock has a market capitalization of $2.75 billion, a PE ratio of -6.92 and a beta of 1.39. The company’s 50-day moving average is $24.13 and its 200-day moving average is $24.83. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the company earned ($0.72) EPS. On average, analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Denali Therapeutics

Several large investors have recently added to or reduced their stakes in DNLI. Rhumbline Advisers lifted its position in Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock valued at $4,525,000 after acquiring an additional 22,900 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Denali Therapeutics by 4.5% during the 2nd quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock worth $4,160,000 after buying an additional 7,766 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Denali Therapeutics by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after buying an additional 2,730 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock worth $12,135,000 after buying an additional 63,058 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock worth $32,913,000 after buying an additional 84,522 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

DNLI has been the subject of a number of recent analyst reports. HC Wainwright decreased their price target on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday. JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Robert W. Baird initiated coverage on Denali Therapeutics in a report on Tuesday. They set an “outperform” rating and a $31.00 price target for the company. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $38.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.